Brokerages Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Target Price at $4.23

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have earned an average recommendation of “Hold” from the thirteen brokerages that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $4.2273.

Several equities research analysts recently weighed in on GDRX shares. The Goldman Sachs Group restated a “neutral” rating and issued a $4.00 target price on shares of GoodRx in a report on Friday, August 7th. UBS Group boosted their price objective on shares of GoodRx from $2.50 to $3.75 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Citigroup upped their price objective on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Wells Fargo & Company raised their target price on shares of GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Wall Street Zen upgraded shares of GoodRx from a “hold” rating to a “buy” rating in a report on Saturday, August 15th.

Insider Activity

In other news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $3.50, for a total value of $4,536,619.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 2,760,995 shares of company stock valued at $9,673,207 over the last 90 days. Company insiders own 5.87% of the company’s stock.

Institutional Trading of GoodRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in shares of GoodRx by 7.3% in the third quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company’s stock valued at $38,947,000 after acquiring an additional 624,182 shares during the period. Ameriprise Financial Inc. boosted its holdings in GoodRx by 4.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock valued at $24,001,000 after purchasing an additional 184,734 shares during the period. Renaissance Technologies LLC boosted its holdings in GoodRx by 1.5% in the 1st quarter. Renaissance Technologies LLC now owns 3,259,738 shares of the company’s stock valued at $6,389,000 after purchasing an additional 48,800 shares during the period. LSV Asset Management grew its position in GoodRx by 20.0% in the 4th quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock worth $7,658,000 after purchasing an additional 471,319 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in GoodRx by 6.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,650,452 shares of the company’s stock worth $7,183,000 after purchasing an additional 152,934 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Stock Up 0.3%

GDRX stock opened at $3.35 on Tuesday. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74. GoodRx has a 1 year low of $1.77 and a 1 year high of $5.81. The company has a fifty day simple moving average of $3.32 and a 200 day simple moving average of $2.75. The firm has a market cap of $1.15 billion, a PE ratio of 83.77, a PEG ratio of 1.66 and a beta of 1.59.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting the consensus estimate of $0.08. The firm had revenue of $200.41 million for the quarter, compared to the consensus estimate of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.09 earnings per share. Sell-side analysts anticipate that GoodRx will post 0.16 EPS for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.